Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.37 |
| ▸ | ESR1 | P03372 | 5/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.36 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430190 | 0.71 | NPC1 (0.53) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18356746 | 0.69 | MAPK1 (0.53) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4032441 | 0.68 | PDPK1 (0.75) | PDPK1HSP90AB1ESR1FGFR1FGFR2 | |
| SCHEMBL12986756 | 0.67 | MAPK1 (0.42) | MAPTKMT2AMEN1PDPK1HSP90AB1 | |
| SCHEMBL6777206 | 0.66 | NPC1 (0.55) | MAPTSMN1; SMN2ALDH1A1ADORA2AADORA1 | |
| SCHEMBL29291190 | 0.66 | TLR8 (0.53) | MAPTKMT2AMEN1ALDH1A1ESR2 | |
| SCHEMBL4026003 | 0.65 | ESR1 (0.54) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14545342 | 0.64 | CNR1 (0.49) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6541647 | 0.64 | DHODH (0.49) | MAPTKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL6356363 | 0.63 | PTPN22 (0.50) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723736-B2 | FOR THERAPY INFLAMMATION, INFLAMMATORY DISEASES, IMMUNOLOGIC DISEASES AND OTHER DISEASES MEDIATED BY TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) AND/OR INTERLEUKIN 6 OR 10 AND/OR ENZYME CYCLOOXYGENASE-2 (COX-2) | THERACOS, INC. | 2004-04-20 | — | — | US | claimed |
| US-20020077333-A1 | Tricyclic compounds and uses thereof | THERACOS, INC. | 2002-06-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077333-A1 | Tricyclic compounds and uses thereof | IL6, TNF, IL2 | MAPT 3486/4885KMT2A 3251/4885MEN1 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.